Duke Clinical Research Institute, Duke University School of Medicine, 2400 Pratt Street, Duke Medicine, Durham, NC, 27705, USA.
AbbVie Pharmaceuticals, Chicago, IL, USA.
Cardiovasc Drugs Ther. 2017 Aug;31(4):445-458. doi: 10.1007/s10557-017-6739-9.
The need for novel approaches to cardiovascular drug development served as the impetus to convene an open meeting of experts from the pharmaceutical industry and academia to assess the challenges and develop solutions for drug discovery in cardiovascular disease.
The Novel Cardiovascular Therapeutics Summit first reviewed recent examples of ongoing or recently completed programs translating basic science observations to targeted drug development, highlighting successes (protein convertase sutilisin/kexin type 9 [PCSK9] and neprilysin inhibition) and targets still under evaluation (cholesteryl ester transfer protein [CETP] inhibition), with the hope of gleaning key lessons to successful drug development in the current era. Participants then reviewed the use of innovative approaches being explored to facilitate rapid and more cost-efficient evaluations of drug candidates in a short timeframe.
We summarize observations gleaned from this summit and offer insight into future cardiovascular drug development.
The rapid development in genetic and high-throughput drug evaluation technologies, coupled with new approaches to rapidly evaluate potential cardiovascular therapies with in vitro techniques, offer opportunities to identify new drug targets for cardiovascular disease, study new therapies with better efficiency and higher throughput in the preclinical setting, and more rapidly bring the most promising therapies to human testing. However, there must be a critical interface between industry and academia to guide the future of cardiovascular drug development. The shared interest among academic institutions and pharmaceutical companies in developing promising therapies to address unmet clinical needs for patients with cardiovascular disease underlies and guides innovation and discovery platforms that are significantly altering the landscape of cardiovascular drug development.
心血管药物开发需要新方法，这促使制药行业和学术界的专家召开了一次公开会议，评估心血管疾病药物发现所面临的挑战并制定解决方案。
新型心血管治疗学峰会首先回顾了将基础科学观察转化为靶向药物开发的正在进行或最近完成的项目的最新实例，重点介绍了成功的案例（蛋白转化酶枯草溶菌素/kexin 型 9 [PCSK9]和 Neprilysin 抑制）和仍在评估中的靶点（胆固醇酯转移蛋白 [CETP]抑制），希望从中汲取成功开发药物的关键经验。与会者随后回顾了正在探索的创新方法，以促进在短时间内快速、更具成本效益地评估候选药物。
我们总结了此次峰会获得的观察结果，并对未来的心血管药物开发提出了见解。
遗传和高通量药物评估技术的快速发展，加上新方法可通过体外技术快速评估潜在的心血管治疗方法，为识别心血管疾病的新药物靶点、在临床前环境中更有效地研究新疗法并提高高通量、以及更快速地将最有前途的疗法推向人体试验提供了机会。然而，行业和学术界之间必须有一个关键的接口来指导心血管药物开发的未来。学术机构和制药公司在开发有前途的疗法以满足心血管疾病患者的未满足临床需求方面的共同利益，为创新和发现平台提供了基础，并指导这些平台显著改变了心血管药物开发的格局。
